The New York Times / Bayer / IG Farben / Pfizer / DuPont / Community Patent Regulation / Bristol Myers / Du Pont / Hoechst / Pharmaceutical Patents Pharmaceuticals / BASF / E.U. / /
Continent
America / Europe / /
Country
Germany / Switzerland / Italy / France / Japan / United States / Portugal / United Kingdom / China / Luxembourg / Spain / Greece / India / Ireland / Denmark / /
Currency
USD / /
Event
Product Issues / Product Recall / Bankruptcy / FDA Phase / Person Communication and Meetings / Company Expansion / /
IndustryTerm
biotechnology / chemical formula / chemical production / chemical product / chemical products / pharmaceutical / paint / chemical patents / food / media stat virtus / pharmaceuticals / chemical and industrial processes / engineered product / chemical processes / chemical industry / chemical market / patent law / chemical entity / chemical knowledge / chemical / ambiguity medical products / industrial products / drug products / /
MedicalCondition
cancer / AIDS / /
Movie
Edison / /
Organization
Supreme Court / Union of Paris / U.S government / World Trade Organization / British government / European Commission / Sargent Committee / FDA / European Union / German Association of the Chemical Industry / Brazilian government / /
Boldrin & Levine: Against Intellectual Monopoly, Chapter 9 Chapter 9: The Pharmaceutical Industry It is often argued that the best case for patents is in the pharmaceutical industry. The fixed cost of innovation is larg